SEC Form 4 · accession 0000899243-16-034104
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean-Frederic Viret
Officer — Chief Financial Officer
Period of report
Nov 18, 2016
Accepted (ET)
Nov 22, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Nov 18, 2016 | M | 3,900 | $13.50 | A | 6,225 | D | |
| Common Stock, $0.0001 par valueF2 | Nov 18, 2016 | S | 3,900 | $28.1936 | D | 2,325 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $13.50 | Nov 18, 2016 | M | 3,900 | D | — | Nov 5, 2024 | Common Stock | 3,900 | 120,948 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- F2The transaction was executed in multiple trades in prices ranging from $27.95 to $28.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F3The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from September 22, 2014 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.